Guided self-help for patients with CFS prior to starting CBT

Research abstract:

Guided self-help for patients with Chronic Fatigue Syndrome prior to starting Cognitive Behavioural Therapy: A cohort study, by Sheila Ali, Kimberley Goldsmith, Mary Burgess, Trudie Chalder in Behavioural and Cognitive Psychotherapy 5 May 2017 [Preprint]

Background:
Previous research suggests that minimal interventions such as self-help guidance can improve outcomes in patients with fatigue or chronic fatigue syndrome (CFS).

Aims:
The aim of the current study was to investigate whether self-help guidance could improve physical functioning, social adjustment and fatigue in a group of patients with CFS who were awaiting CBT at a clinic in secondary care.

Method:
Patients completed questionnaires at their initial assessment (baseline), immediately before beginning CBT (pre-treatment), and after their last session of CBT (end of treatment). The primary outcome was physical functioning, and the secondary outcomes were social adjustment and fatigue. Multi-level linear models were used to assess change over time after adjustment for gender and age.

Results:
Multi-level models revealed that from baseline to pre-treatment, patients showed statistically significant improvements in physical functioning, but there were no statistically significant improvements in fatigue or social adjustment. However, all the primary and secondary outcomes showed statistically significant changes after CBT.

Conclusions:
The findings of this study indicate that self-help guidance may be beneficial for patients with CFS who are awaiting CBT treatment or those who are unable to access specialist treatment in their local area.

See a discussion at Phoenix rising which raises questions about the methodology in this study.

NB The full paper is behind a firewall.

Posted in News | Tagged , , , , | Comments Off on Guided self-help for patients with CFS prior to starting CBT

On your marks GETSET: don’t go – major Graded Exercise ME/CFS trial underwhelms (again)

Health rising blog post, by Cort Johnson, 25 June 2017: On Your Marks GETSET: Don’t Go – Major Graded Exercise ME/CFS Trial Underwhelms (Again)

 

The Lancet — one of the most highly regarded journals in the world — is back on the chronic fatigue syndrome (ME/CFS) community’s front page. That’s probably enough to either elicit curses from ME/CFS patients or to produce a strong desire to hide under one’s bed.  Lancet’s ME/CFS offerings of late have been dominated by the PACE CBT trials and their controversies.  Lancet’s refusal to retract that study is bad enough; it’s unwillingness to allow skeptics to publish a letter stating their concerns (after Lancet asked the PACE authors whether they should) was just plain weird. It’s editor, Richard Horton, can hardly control himself when talking about the ME/CFS community.

Lancet is back with another ME/CFS behavioral study…
Now Lancet is back with guess what? Another behavioral chronic fatigue syndrome trial. To make sure EVERYONE can read it, they put it in their free article section. Lancet has occasionally allowed dissenters to publish letters but there’s no doubt as to the journals pro-behavioral orientation to this disease. What’s more doubtful is whether the studies they’re publishing are helping their case.

Clark, LV, Pesola, F, Thomas, JM, Vergara-Williamson, M, Beynon, M, and White, PD. Guided graded exercise self-help plus specialist medical care versus specialist medical care alone for chronic fatigue syndrome (GETSET): a pragmatic randomised controlled trial. (published online June 22.) Lancet. 2017

As usual in UK-funded CBT/GET trials the trial was very large (n=211), far larger than non-CBT/GET trials in ME/CFS.  in size. That size differential alone gives CBT/GET an advantage because it gives researchers more ability to tease out less subtle effects.

Another advantage — crappy entry criteria. The patients had to meet the NICE guidelines — a slightly more restrictive version of the much derided and now officially debunked (see the AHRQ report) Oxford criteria. Since most of the patients chose walking as their exercise activity of choice we can assume that not many of the really ill were included.

NICE Guidelines:

  • 4 months of clinically evaluated, unexplained, persistent or relapsing fatigue with a definite onset resulting in a substantial reduction in activity that is characterized by post-exertional malaise or fatigue, or both.
  • One of the following symptoms:  difficulty sleeping, headaches, cognitive dysfunction, general malaise or flu-like symptoms, painful lymph nodes, sore throat, physical or mental exertion making symptoms worse, dizziness or nausea, palpitations, or multi-site muscle or joint pain without evidence of inflammation.

One wonders when the U.K. and the Netherlands are going to say enough is enough with CBT/GET. How much more, after all, can one say about a therapy’s effectiveness after dozens of studies have been published? They’re certainly not giving up yet.

This study’s twist is that it employed a graded exercise self-help component it’s proponents could be administered cheaply.  The participants met with a physiotherapist up to four times to ensure that they were doing the program correctly, but otherwise worked off a GET handbook containing a six-step graded exercise program that took about 12 weeks to complete.

The participants (half were in the GET program and half were in normal care) were assessed at baseline, four weeks after the trial ended, and 12 months after the start of the trial. The Chalder Fatigue scale and Physical Functioning subscale of the SF-36 tests were used to assess results. Another questionnaire asked the patients how much better their health was after the trial.

As in the PACE trial, some changes were made in the study protocol but I’ll leave it to David Tuller, Julie Rehmeyer, Tom Kindlon, Graham and other patient statistical experts to parse out if they might have affected the study.

The Graded Exercise Therapy Program
The Graded Exercise Therapy Booklet (find it here) is humble in many of its promises. It does not promise that ME/CFS patients will be cured or that they will be able to do all the activities they did in the past. It also does not delegitimize problems with exercise or suggest that ME/CFS is all in one’s mind; instead it suggests that prior exercise attempts may have failed because they were too rigorous.

Ignoring the fact that the program has not been tested in more severely ill ME/CFS patients, the booklet states:

A GET programme will help you gradually improve your ability to undertake some of the physical activities that you have been unable to do since becoming unwell.

The short theory section unmasks the limitations of GET and the program. GET, it turns out, is primarily designed to address two factors: deconditioning and the boom/bust cycle.

Deconditioning
Deconditioning is real in ME/CFS but nothing suggests it causes the disease.
It’s clear that deconditioning is present in some ME/CFS patients; in fact, it’s unavoidable. Any disease that so severely limits functioning is going to cause some deconditioning — a physiological state of inactivity which produces a horde of negative effects.(Hold your breath)

Deconditioning results in decreased muscle strength, structural changes to the nerves and muscles, reduced co-ordination and balance, connective tissue thickening and muscle shortening that affects movement (hence the stretching exercises), reduced blood volume, increased inflammation, bone demineralization, stroke volume (heart), thickened blood, orthostatic intolerance, decreased gut motility, constipation, increased risk of diabetes, cognitive problems, sleep disturbances, irritability and depression. (!)

Unfortunately it’s really hard to determine how much bedrest is needed to cause deconditioning or how much activity is needed to stave it off. (One website did say that even by short periods of upright activity can stave off some effects of deconditioning.) It’s clear, though, that deconditioning process can begin within days of being bedbound. Ten days of bed rest in healthy adults resulted in significantly reduced maximum aerobic capacity.  Muscle wasting and problems with orthostatic intolerance can occur within days.

Deconditioning is real in ME/CFS but nothing suggests it causes the disease.

Unfortunately for the purveyors of GET and their emphasis on deconditioning, while deconditioning is surely present in some ME/CFS patients, there’s no evidence that deconditioning plays a major role in producing ME/CFS.  Systrom’s fascinating invasive CPET  study of ME/CFS and other patients with idiopathic or unexplained exercise issues uncovered a heart filling pattern that is opposite to that found in deconditioning.  The results of other exercise studies argue against deconditioning being a core element of ME/CFS.  Deconditioned people, after all, should improve on a second exercise study; many people with ME/CFS do worse. Even Wyller’s studies (Wyller is a strong proponent of CBT/GET) find no evidence that deconditioning contributes to the core issues in ME/CFS.

If deconditioning is present in some ME/CFS patients, but is not causing ME/CFS, a program like GET should have some positive effects but not many.  It should help people around the edges but not significantly affect their core issues. That’s exactly what happened in this study.

The Boom-Bust Cycles
The booklet indirectly acknowledges the major role post-exertional malaise plays in ME/CFS by emphasizing that getting enough rest and avoiding overdoing activities that result in a crash or relapse is critical to the success of the program.

(Note the unusual blend of “treatments” in this program: one is designed to slowly increase activity; another to limit it and ensure that ample rest is present.)

The Six Step GETSET  Program 
The GETSET program consists of the following steps:

  1. Stabilize activity levels: Use a diary to stabilize one’s activity levels and avoid boom-bust cycles for a week or so.
  2. Begin a stretching program: See booklet for numerous stretching exercises.
  3. Decide on an enjoyable, regular activity goal
  4. Add one activity/exercise: About 2 to 3 weeks in, add an activity you can do without making you worse — even on a bad day.  Do not do more than your planned activity, even if you feel up to it.  Take a short rest after the activity/exercise in a sitting position.
  5. Increase exercise duration: Increase the amount of exercise by 20% a week. If you only increase exercise (and keep your baseline activity intact), the booklet says “your body will adapt”. The program shows a person starting out at 10 mins a day, ending up with 30 mins a day after 12 weeks.
  6. Increase exercise intensity: Once you’re able to walk 30 minutes a day, five days a week, increase the intensity (e.g. by walking faster) very slowly over several months.

Notes from the booklet: Maintain as much physical activity as you can, even if it is uncomfortable. If you have to take a break, get back to your exercises program as soon as possible. An increase in symptoms does not necessarily mean that harm is being done.

Results
The results of the 200-plus study were decidedly underwhelming.  Yes, a higher percentage of patients using the remote form of GET improved than those receiving normal care, but not by much. On  a scale of 0-33, with 0 meaning no fatigue is present, the GET patients’ fatigue improved by just 4 points, or about 12%.  GET moved the needle on physical functioning — an arguably more important measure — by even less (just 6 points out of a hundred). That outcome was similar to a Cochrane Review which found that GET produced “little or no difference in physical functioning, depression, anxiety and sleep”.

When asked to rate their overall health following the trial, the good news for GET proponents was that a much higher percentage of GET participants reported feeling much better than did those receiving normal care.  The bad news was that the percentage of those really benefiting from the program was small, indeed, with just 1 out of 5 reporting feeling “much better” or “very much better”.

With few patients reporting they were much or very much improved by the protocol, the results were underwhelming

More good news for the GET proponents included the low dropout and low serious adverse events rates. The bad news was that only about 40% of the participants (42%) adhered to the protocol “well” or “very well”. That suggested that either some stopped before an adverse event could occur or that the protocol was simply too difficult to manage for many.  An easily manageable protocol is a key goal in therapeutic trials; treatments are worth little if they’re too difficult to adhere to.

The elephant in the room was (once again) the missing activity or actometer measurements. Since GET is specifically designed to increase activity levels measuring that increase — easily done with an actometer — having one seems like a no-brainer, yet once again actometers were not included.

In the end the improvement was similar to what one might have expected in a population in which  some deconditioning was present. It’s possible that the remote GET program may have improved some patients’ deconditioning (the worse off patients did better) but failed to move the bar in a major way in the disease itself. Physical functioning was barely touched and most in the study (80%) reported that their health was not much or very much better after doing the remote GET protocol.

There’s nothing the matter with — and everything right with — an appropriate exercise program. The problem is the outsize influence CBT/GET studies have had on how ME/CFS is viewed and treated. The GET SET program’s detailed (diary-based) approach to managing activity levels seems encouraging but it was surely optimistic in its projection that activity levels would climb over time. It’s assertion that symptom exacerbation doesn’t reflect harm was questionable as well. (Symptom exacerbation (muscle soreness, fatigue), of course, occurs with any increase in exercise but is brief and the exerciser is left stronger not weaker.)  Staci Stevens’ and Dr. Klimas’ heart-rate based activity management programs — specific exercises with rest times — provides a more sophisticated approach for people with ME/CFS. Learn how to do those in the link below.

Learn how to do a heart rate based exercise program in Health Rising’s Exercise Resource Center for Chronic Fatigue Syndrome (ME/CFS)

Check out a report of a patient who significantly increased her activity levels and fitness and even cardiovascular measures using Staci Stevens’ heart-rate approach, which required that she keep her heart rate below a certain level.

The Lancet Effect
Lancet, not surprisingly, filled its comment age with CBT/GET proponents who lauded the study findings — demonstrating again what a low bar for success exists in these studies. Daniel Clauw, M.D. — a fibromyalgia, not an ME/CFS specialist — lead the applause stating, “The finding that graded exercise therapy is effective even when exercise is not being witnessed and directly guided by a physiotherapist is a substantial advance”.

Clauw turned a study which significantly benefited a minority of the participants into a blanket statement that GET was effective for all.

But effective for whom? The study’s own findings indicated that most ME/CFS patients in the trial  (66%) were not significantly improved and less than 20% rated their health as much better at the trial’s end. (This is in a study put together using a definition not that dissimilar from the Oxford one, a lax criterion).

The results were decidedly underwhelming and the lead author’s statement, read carefully, reflected that: remote GET,  she said, helped “some” patients “manage” their symptoms.

“We found that a self-help approach to a graded exercise programme, guided by a therapist, was safe and also helped to reduce fatigue for some people with chronic fatigue syndrome, suggesting that it might be useful as an initial treatment for patients to help manage symptoms of chronic fatigue syndrome. Dr. Lucy Clark

Symptom management is fine, but effective symptom management should affect more than a minority of participants. Even better, of course, would be a cure. One wonders when the U.K. is going to give up its decades long obsession with CBT/GET and actually try to get at the cause of this disease. Results like these should help U.K. administrators make that switch.

We pretty much know what behavioral therapies can do: they can help with fatigue for a few but do little to improve physical functioning.  Neither come close to curing this disease and few, if anyone  anymore, are suggesting that they can. The results from both the PACE trial (even in its original version), and this study suggests it’ time for the U.K. and others to get off the behavioral bandwagon and spend some money trying to really help ME/CFS patients.

Read the comments following this article

Posted in News | Tagged , , | Comments Off on On your marks GETSET: don’t go – major Graded Exercise ME/CFS trial underwhelms (again)

Chronic fatigue & idiopathic intracranial hypertension

Medical hypothesis abstract:

Chronic fatigue syndrome and idiopathic intracranial hypertension: Different manifestations of the same disorder of intracranial pressure? by J. Nicholas P. Higgins, John D. Pickard, Andrew M.L. Lever in Medical Hypotheses Vol 105, pp 6-9, August 2017 [Available online 24 June 2017]

Though not discussed in the medical literature or considered in clinical practice, there are similarities between chronic fatigue syndrome and idiopathic intracranial hypertension (IIH) which ought to encourage exploration of a link between them.

The cardinal symptoms of each – fatigue and headache – are common in the other and their multiple other symptoms are frequently seen in both. The single discriminating factor is raised intracranial pressure, evidenced in IIH usually by the sign of papilloedema, regarded as responsible for the visual symptoms which can lead to blindness.

Some patients with IIH, however, do not have papilloedema and these patients may be clinically indistinguishable from patients with chronic fatigue syndrome. Yet IIH is rare, IIH without papilloedema (IIHWOP) seems rarer still, while chronic fatigue syndrome
is common. So are the clinical parallels spurious or is there a way to reconcile these conflicting observations?

We suggest that it is a quirk of clinical measurement that has created this discrepancy. Specifically, that the criteria put in place to define IIH have led to a failure to appreciate the existence, clinical significance or numerical importance of patients with lower level
disturbances of intracranial pressure. We argue that this has led to a grossly implausible distortion of the epidemiology of IIH such that the milder form of the illness (IIHWOP) is seen as less common than the more severe and that this would be resolved by recognising a connection with chronic fatigue syndrome.

We hypothesise, therefore, that IIH, IIHWOP, lesser forms of IIH and an undetermined proportion of chronic fatigue cases are all manifestations of the same disorder of intracranial pressure across a spectrum of disease severity, in which this subset of chronic fatigue syndrome would represent the most common and least severe and IIH the least common and most extreme.

 

Posted in News | Tagged , , , , , | Comments Off on Chronic fatigue & idiopathic intracranial hypertension

ME/CFS: A new explanation – and cure from Dr Willy Eriksen?

Tracy Duvall blog post, 10 June 2017: ME/CFS: A new explanation – and cure?

In a recent paper, Dr. Willy Eriksen proposes a complete explanation for the development, diversity, and persistence of myalgic encephalomyelitis, aka chronic fatigue syndrome (ME/CFS). He also suggests a possible cure. Seeing that this potentially groundbreaking research was attracting little attention, I contacted Dr. Eriksen and interviewed him via email. This post contains a summary of his hypothesis, which I’ve tried to present in everyday language.

Other posts contain:

1) the interview, which contains considerable new information about his hypothesis, and 2) my understanding of how Eriksen’s model fits with other research—and with my experience.

Eriksen holds an MD and PhD and is a research professor at the Norwegian Institute of Public Health.

Ultra-short summary
…Clumps of immune cells form in one or more key spots along the nervous system. Epstein-Barr virus (EBV) infects the clump(s), and this causes inflammation in the area. This inflammation provokes a reaction in the nervous system, which directly and indirectly accounts for the symptoms of ME/CFS. Extracting a patient’s immune cells, priming them to fight EBV, and returning them to his or her body might cure the disease.

Read the full blog post for more information

 

Posted in News | Tagged , , , , | Comments Off on ME/CFS: A new explanation – and cure from Dr Willy Eriksen?

Further commentary on the PACE trial: biased methods & unreliable outcomes

Article abstract:

Further commentary on the PACE trial: Biased methods and unreliable outcomes, by Keith J Geraghty in Journal of Health Psychology [First Published June 14, 2017, Editorial]

Geraghty in the year 2016, outlines a range of controversies surrounding publication of results from the PACE trial and discusses a freedom of information case brought by a patient refused access to data from the trial.

The PACE authors offer a response, writing ‘Dr Geraghty’s views are based on misunderstandings and misrepresentations of the PACE trial’. This article draws on expert commentaries to further detail the critical methodological failures and biases identified in the PACE trial, which undermine the reliability and credibility of the major findings to emerge from this trial.

Posted in News | Tagged , | Comments Off on Further commentary on the PACE trial: biased methods & unreliable outcomes

What is known about severe & very severe CFS? A scoping review

Review abstract:

What is known about severe and very severe chronic fatigue syndrome? A scoping review, by Victoria Strassheim, Rebecca Lambson, Katie L. Hackett, Julia L. Newton in Fatigue: Biomedicine, Health & Behavior [Preprint June 19, 2017]

Background:
Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) affects 0.4% of the population. It is characterised by disabling fatigue and a combination of self-reported symptoms which include impairments in concentration, short-term memory, sleep disturbances, post-exertional malaise and musculoskeletal pain.

There are four categories of severity in the CFS/ME population: mild; moderate; severe; and very severe which are expanded on elsewhere and adopted by the National Institute for Health and Care Excellence [NICE. Chronic fatigue syndrome/myalgic
encephelomyelitis diagnosis and management in adults and children; 2007].

Objective:
Identify research relating to those severely and very severely affected by CFS/ME.

Methods:
We searched electronic databases for relevant studies using pre-defined search terms: ‘chronic fatigue syndrome’ and ‘severe’ which covers ‘severe’ and ‘severely’. Included were English language papers published in full that discretely identified severely and very severely affected CFS/ME populations from the broader CFS/ME population.

Results:
Over 2000 papers were reviewed and 21 papers met the selection criteria.  The capture produced both adult and paediatric populations with a variety of methodologies. Wide differences in illness characterisation, definition and measurement were found. Case studies reported that in extreme presentations very severe CFS/ME individuals may be confined to bed, requiring reduced light and noise exposure.

Conclusion:
This review highlights the limited research focusing on the severely affected CFS/ME population. The heterogeneity of the condition contributes to the lack of consensus concerning definitive diagnostic criteria and functional measures to assess disability. Focused research to understand the disease characteristics of the most severely ill will
help to advance our understanding of possible phenotypes associated with distinct severity categories.

Posted in News | Tagged , , , , | Comments Off on What is known about severe & very severe CFS? A scoping review

Defense of the PACE trial is based on argumentation fallacies

Article abstract:
Defense of the PACE trial is based on argumentation fallacies, by Steven Lubet in Journal of Health Psychology [Published June 14, 2017]

In defense of the PACE trial, Petrie and Weinman employ a series of misleading or fallacious argumentation techniques, including circularity, blaming the victim, bait and switch, non-sequitur, setting up a straw person, guilt by association, red herring, and the parade of horribles. These are described and explained.

 

Posted in News | Tagged , , , | Comments Off on Defense of the PACE trial is based on argumentation fallacies

Understanding severely affected CFS: the gravity of the situation

Review abstract:

Understanding severely affected chronic fatigue syndrome (CFS): The gravity of the situation, by Victoria Strassheim, Robert Ballantine, Katie L. Hackett, James
Frith, Julia L. Newton in Physical Therapy Reviews [Preprint May 25, 2017]

Objective:
To describe how the effects of gravity may adversely affect the neuro-cardiovascular physiology of individuals with severe Chronic Fatigue Syndrome (CFS).

Design:
A narrative review of the literature relating to microgravity, orthostatic intolerance and severe CFS. Emphasis is placed on the clinical significance and implications for the management of patients with severe CFS, with suggestions for future rehabilitation and physical interventions.

Results:
Physiological functions in humans have evolved to counter the effects of gravity, in particular the neuro-cardiovascular system. Reducing exposure to gravity will result in deconditioning of these systems. Many of the symptoms experienced by astronauts returning to Earth are shared by those with severe CFS.

Prolonged periods in the supine position create an environment similar to microgravity – the mechanism through which we propose orthostatic intolerance develops in CFS. However, there are also some physiological changes present in CFS which may exacerbate these changes. Studies have shown that some CFS individuals have  hypovolaemia unrelated to deconditioning. This pre-existing hypovolaemia may make the neuro-cardiovascular system more vulnerable to the effects of bed rest in those individuals with CFS.

Conclusion:
Severely affected CFS individuals may be more susceptible to a specific type of deconditioning, related to reduced exposure to gravity, due to pre-existing vulnerabilities in their cardiovascular and autonomic nervous systems. Rehabilitation which targets the neuro-cardiovascular system and its response to upright posture may improve function and symptoms of severely affected CFS individuals.

Posted in News | Tagged , , , , , , , , , , | Comments Off on Understanding severely affected CFS: the gravity of the situation

ME/CFS diagnosis & management in young people: a primer

Review article:

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: a Primer, by Peter C. Rowe,  Rosemary A. Underhill,  Kenneth J. Friedman,  Alan Gurwitt,  Marvin S. Medow,  Malcolm S. Schwartz,  Nigel Speight,  Julian M. Stewart,  Rosamund Vallings and  Katherine S. Rowe in Front. Pediatr., 19 June 2017

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease that affects children and adolescents as well as adults. The etiology has not been established.

While many pediatricians and other health-care providers are aware of ME/CFS, they often lack essential knowledge that is necessary for diagnosis and treatment. Many young patients experience symptoms for years before receiving a diagnosis.

This primer, written by the International Writing Group for Pediatric ME/CFS, provides information necessary to understand, diagnose, and manage the symptoms of ME/CFS in children and adolescents.

ME/CFS is characterized by overwhelming fatigue with a substantial loss of physical and mental stamina. Cardinal features are malaise and a worsening of symptoms following minimal physical or mental exertion. These post-exertional symptoms can persist for hours, days, or weeks and are not relieved by rest or sleep. Other symptoms include cognitive problems, unrefreshing or disturbed sleep, generalized or localized pain, lightheadedness, and additional symptoms in multiple organ systems.

While some young patients can attend school, on a full or part-time basis, many others are wheelchair dependent, housebound, or bedbound. Prevalence estimates for pediatric ME/CFS vary from 0.1 to 0.5%. Because there is no diagnostic test for ME/CFS, diagnosis is purely clinical, based on the history and the exclusion of other fatiguing illnesses by physical examination and medical testing. Co-existing medical conditions including orthostatic intolerance (OI) are common.

Successful management is based on determining the optimum balance of rest and activity to help prevent post-exertional symptom worsening. Medications are helpful to treat pain, insomnia, OI and other symptoms.

The published literature on ME/CFS and specifically that describing the diagnosis and management of pediatric ME/CFS is very limited. Where published studies are lacking, recommendations are based on the clinical observations and practices of the authors.

Read more

Posted in News | Tagged , , , , , , , , , , | Comments Off on ME/CFS diagnosis & management in young people: a primer

Could we finally have a definitive biomarker for ME/CFS?

ME Research UK blog post, 9 June 2017: Could we finally have a definitive biomarker for ME/CFS?

It’s a recurring theme, but the diagnosis of ME/CFS is severely hampered by the lack of a test that can distinguish people with the illness from those without. This is a challenge in many diseases, but particularly in ME/CFS which affects so many different systems of the body.

ME/CFS is currently identified by the presence of specific signs and symptoms, but there are several different criteria in use, and much debate over which are the most precise or appropriate. The quest for a biomarker is therefore a top priority since an accurate diagnosis is essential for patients to receive the medical care they need.

Generally speaking, biomarkers are measurable substances or processes in the body that can indicate the risk, presence or severity of a disease, or how well it will respond to a specific treatment.

For example, a high white blood cell count may indicate the presence of an infection, while raised levels of prostate-specific antigen in the blood are associated with an increased risk of prostate cancer.

Researchers have looked at a number of different measures as potential biomarkers for ME/CFS, including brain imaging findings, ECG abnormalities, and immunosignatures based on antibodies in the blood.

In fact, ME Research UK has recently funded work to look for an immunosignature that can predict patients’ responses to rituximab therapy.

New research from a team in Australia, led by Prof. Brett Lidbury at the Australian National University in Canberra, has added another potential biomarker to this list.

Prof. Lidbury has a longstanding interest in the search for biomarkers for ME/CFS, and ME Research UK recently awarded his group funding to analyse genetic data which might provide clues about the mechanisms of the disease.

But in this recent study, published in the Journal of Translational Medicine, the team focused on a different potential biomarker: activin.

The two types of activin (A and B) are produced in several organs in the body, and have a number of different roles, including regulation of the menstrual cycle, and involvement in metabolism and wound repair.

Prof. Lidbury is interested in two of its functions which have particular relevance to ME/CFS, namely the control of inflammation and muscle mass. Inflammation is important because the immune system is thought to be involved in the illness, while muscle mass will have an obvious influence on muscle weakness and pain.

The researchers took blood samples from 45 patients with ME/CFS (as defined by the Canadian Diagnostic Criteria) and from 17 healthy controls. Concentrations of both activin A and activin B were measured (as they have some different functions), as well as follistatin (a binding protein that regulates levels of activin).

Levels of activin B in the blood were markedly higher in the ME/CFS patients than in the healthy individuals (and also higher than in a previously studied normal group), whereas activin A and follistatin levels were no different.

This exciting finding suggests that the combination of elevated activin B and normal activin A may represent a useful biomarker for the presence of ME/CFS, although this would need to be validated in larger groups of patients.

Another intriguing prospect is whether follistatin might have some value as a treatment for ME/CFS since it can inhibit the actions of activin B. In fact, follistatin could have a two-pronged attack because it also blocks myostatin, a protein that inhibits muscle cell growth.

Prof. Lidbury’s study has certainly borne fruit, giving us a potential diagnostic biomarker for ME/CFS, as well as some hope for a new treatment. It’s early days on both fronts, however, so we will be keeping a close eye on further developments from this group.

Posted in News | Tagged , , , | Comments Off on Could we finally have a definitive biomarker for ME/CFS?